alexa Adenosine Receptors Ligand Modulated Nanoparticle Targeting To Human Breast Cancer Cells Via Over Expressed Adenosine Receptors
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Nanotek & Expo
December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Rajan Swami, Indu Singh, Wahid Khan and Ramakrishna Sistla
Accepted Abstracts: J Nanomed Nanotechnol
DOI: 10.4172/2157-7439.S1.019
G protein coupled cell surface adenosine receptors (ARs) are found to be up regulated in various tumor cells like breast, prostate and brain tumors. The present study was performed to investigate the efficiency of adenosine receptors ligand to target human breast cancer cell lines MCF-7. Solid lipid nanopartlces (SLN) were prepared by solvent emulsification and evaporation process and further evaluated by various techniques like X-Ray diffraction (XRD), Dynamic light scattering (DLS). Drug loaded SLN were surface modified with ARs ligand using carbodiimide coupling. Conjugation was confirmed using Infrared spectroscopy (IR). In vitro drug release was performed by dialysis bag method and conjugated SLN were found to give better sustain drug release as compared to unconjugated nanoparticles and drug solution. Cell toxicity assay were executed and results were encouraging with remarkable decrease in IC50 values as compared to drug encapsulated unconjugated lipidic nanoparticles and drug control and these results were further substantiated by improved cell uptake assay. Hence, this novel ARs ligand has the capability to target breast tumors and incorporating this ligand on surface of SLN modulates the delivery of nanoparticles specifically to ARs overexpressed tumos.
Rajan Swami has completed her MS from NIPER-Ahmadabad, India. Currently, he is a doctoral student in Department of Pharmaceutics, NIPER-Hyderabad, working under the mentorship and co-mentorship of Dr. Ramakrishna Sistla, Scientist E-II, CSIR-Indian Institute of Chemical Technology, Hyderabad, India and Dr. Wahid Khan, Assistant Professor, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, India respectively. He was always a front runner in formulating novel drug delivery systems like dendrimers and nanopartcles for gene delivery. He has been working on conjugated nanoparticles for effective targeting to tumors, rheumatoid arthritis and brain diseases like Alzheimers, Parkinson disease etc.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version